William Blair analyst Brandon Vazquez has maintained their bullish stance on IRTC stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight iRhythm Technologies’ strong performance and future potential. The company reported second-quarter sales that exceeded expectations by $12 million, prompting management to raise their guidance by $30 million. This increase is largely attributed to robust performance in core monitoring and contributions from Zio AT and innovative channels.
Additionally, new accounts that have recently adopted the comprehensive Zio offering are surpassing expectations, suggesting sustained growth in the near term. Vazquez also notes the potential for continued adoption of Zio AT and innovative channels, which could drive durable growth of over 20% with improving margins. With a new product launch anticipated in 2026 and shares trading at a favorable multiple of future sales, Vazquez maintains an Outperform rating for iRhythm Technologies.
Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, Elanco Animal Health, and PROCEPT BioRobotics. According to TipRanks, Vazquez has an average return of -0.6% and a 33.33% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $180.00 price target.